Alzamend Neuro Launches Phase II Trial for Next-Gen Lithium Therapy in Bipolar Disorder

Alzamend Neuro Launches Phase II Trial for Next-Gen Lithium Therapy in Bipolar Disorder

By, Admin 17 March 2026

A new approach to one of psychiatry’s oldest treatments is now moving into the next stage of clinical development.

Alzamend Neuro has announced the initiation of a Phase II clinical trial evaluating its lead candidate, AL001, in patients with Bipolar Disorder Type I.

The trial is being conducted at Massachusetts General Hospital, marking a key step toward developing a safer, more targeted lithium therapy.

Why Reinvent Lithium?

Lithium has been the gold standard treatment for bipolar disorder for over 35 years.

But it comes with serious limitations:

  • Narrow therapeutic window
  • Risk of kidney and thyroid toxicity
  • Need for frequent therapeutic drug monitoring (TDM)

This makes treatment effective—but difficult to manage.

The Core Idea Behind AL001

AL001 is designed to solve a simple but critical problem: Deliver more lithium to the brain—and less to the rest of the body.

Potential Advantages:

  • Higher brain-targeted lithium delivery
  • Lower systemic exposure
  • Reduced risk of side effects and toxicity
  • Potential elimination of routine TDM

If successful, this could significantly improve patient adherence and safety.

Inside the Phase II Trial

The study uses a crossover design to directly compare AL001 with traditional lithium.

Trial Structure:

  • Small cohorts of 6 participants each
  • Two treatment sequences:
    • AL001 → lithium carbonate
    • Lithium carbonate → AL001
  • Each treatment period lasts 14 days
  • 14-day washout between treatments

Advanced Monitoring Techniques:

Participants will undergo:

  • 24-hour pharmacokinetic blood sampling
  • MRI and MRS neuroimaging
  • High-resolution brain lithium mapping

These tools allow researchers to measure:

  • Lithium levels in blood vs brain
  • Distribution across specific brain regions
  • Effects on brain metabolism and biomarkers

Cutting-Edge Imaging Driving the Study

The trial leverages advanced imaging developed at Harvard-linked research centers, including:

  • MRI and spectroscopy techniques for lithium tracking
  • A specialized engineered head coil for whole-brain imaging

This enables something rarely done in psychiatry: Direct measurement of how much drug actually reaches the brain.

Built on Promising Early Data

Earlier studies of AL001 showed:

  • Good tolerability across dose levels
  • Ability to maintain lithium levels below toxicity thresholds
  • Higher brain concentrations at lower doses (in preclinical models)

A maximum tolerated dose (MTD) has already been identified, designed to:

  • Avoid toxic plasma levels
  • Reduce the need for monitoring
  • Be suitable for vulnerable populations, including Alzheimer’s patients

Beyond Bipolar Disorder

While this Phase II trial focuses on bipolar disorder, the broader ambition is much bigger.

Alzamend Neuro is exploring AL001 across:

  • Major depressive disorder (MDD)
  • Alzheimer's disease
  • Post-traumatic stress disorder (PTSD)

The goal: create a platform lithium therapy for multiple neuropsychiatric conditions.

The Bigger Picture: Modernizing Legacy Therapies

This program reflects a growing trend in drug development:

1. Re-engineering proven drugs

Instead of replacing lithium, improve how it’s delivered.

2. Precision targeting

Focus on where the drug acts, not just how much is given.

3. Reducing treatment burden

Eliminate monitoring and side effects that limit real-world use.

Final Take

The launch of this Phase II trial puts AL001 at a critical inflection point.

If it can deliver lithium more safely and effectively, it could transform how clinicians treat not just Bipolar Disorder Type I—but a range of brain disorders.

Sometimes, the biggest breakthroughs don’t replace old drugs. They make them finally work the way they were meant to.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!